Market Intelligence for Neuronal Nicotinic Acetylcholine Receptor Alpha 4 Subunit Drug Development & High-Purity Reagents for Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CHRNA4 (α4 nAChR subunit) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | CHRNA4 Promise-ORF Lentivirus – Full-length ORF for stable cell line generation. Co-transduction with CHRNB2 recommended for functional α4β2 heteromeric receptors. | View CHRNA4 Products |
| Partner Subunit | CHRNB2 (Beta-2 Subunit) – Essential heteromeric partner for ligand-gated ion channel formation. Sequence Verified. | View CHRNB2 Products |
| Selectivity Control | CHRNA7 (Alpha-7 Subunit) – Homomeric nicotinic receptor homolog for counter-screening assays. | View CHRNA7 Products |
| Related Target | CHRNA3 (Alpha-3 Subunit) – Alternative neuronal nAChR subunit; forms α3β4 receptors with distinct pharmacology. | View CHRNA3 Products |
| Related Target | CHRNB4 (Beta-4 Subunit) – Alternative beta subunit; pairs with alpha3 for ganglionic receptor studies. | View CHRNB4 Products |
| Antigen | CHRNA4 Mutant / Recombinant Protein – High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View CHRNA4 Products |
| Benchmark Ab | Anti-CHRNA4 Control Antibody – Recombinant positive control. Sequence Verified. | View CHRNA4 Products |
| Validator | CHRNA4 siRNA Set – For specific knockdown verification in stable cell lines. | View CHRNA4 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heteromeric Assembly (α4β2 Pentamer) | Dual-promoter lentivirus or co-transduction system; HEK293T optimized for ion channel subunit assembly with native glycosylation patterns. |
| Selectivity vs Homomeric α7 | CHRNA7 homolog available for parallel binding and functional assays; sequence divergence verified by mass spec. |
| Endotoxin Sensitivity in Neuronal Assays | Endotoxin <1EU/μg; Suitable for electrophysiology and calcium flux without cellular toxicity artifacts. |
| Native Conformation Preservation | Mammalian (HEK293) expression system maintains post-translational modifications critical for ligand binding pockets. |
| Lack of Reliable Controls | Sequence-verified benchmark reagents and High Purity (>95%) materials provided. |
| Target Validation | Validated siRNA included for specificity checks and functional knockdown. |
Live CHRNA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Receptor Pharmacology Research
- ➤ ADNFLE Mutation & Resistance Analysis
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for selective CHRNA4-targeting therapeutics is intensifying. Major players are shifting focus from broad-spectrum nicotinic agonists to subunit-selective positive allosteric modulators (PAMs). As first-generation partial agonists (e.g., Pfizer's Varenicline for smoking cessation) face efficacy ceilings in CNS disorders, the next wave of R&D is targeting rare genetic epilepsies (ADNFLE) through gene therapy and precision cognitive enhancement with reduced peripheral side effects. Key gain-of-function mutations such as rs121909580 (in ENFL1) are being actively studied for personalized approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Partial Agonist | Pfizer (Varenicline legacy) | Smoking Cessation | Selectivity vs α3β4 and muscle receptors (Need homolog panel) |
| Positive Allosteric Modulator (PAM) | Targacept, AstraZeneca, Novartis | ADNFLE, Parkinson's, Cognition, Alzheimer's | Calcium Flux & Electrophysiology (Need stable α4β2 cell lines) |
| Targeted Biologics | Emerging Biotechs | Neuropathic Pain | Binding Assays (Need native cell surface expression) |
| Gene Therapy | Biotech Startups (Rare Disease) | ADNFLE (Loss-of-function) | Functional complementation assays (Need high-titer CHRNA4 lentivirus) |
| Peptide Toxins | Academic / Discovery Phase | Pain, Autoimmune | Subunit-specific binding (Need CHRNA4 vs CHRNA7 proteins) |
Note: TarMart provides lentivirus, antibodies, proteins, and siRNA for all listed targets, enabling rapid generation of stable cell lines and robust selectivity panels.